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a  b  s  t  r  a  c  t
Type  2  diabetes  mellitus  has recently  been  linked  to an  increased  fracture  risk. Since  bone  mass  seems
to  be  normal  to elevated  in patient  with  type  2 diabetes,  the  increased  fracture  risk  is  thought  to  be  due
to  both  an  increased  falling  frequency  and  decreased  bone  quality.  The  increased  falling  frequency  is
mainly  a result  of  complications  of  the  disease  such  as a retinopathy  and  polyneuropathy.  Bone  quality  is
affected  through  changes  in  bone  shape,  bone  micro-architecture,  and  in  material  properties  such as  bone
mineralization  and  the  quality  of collagen.  Commonly  used  methods  for predicting  fracture  risk  such  as
dual energy  X-ray  absorptiometry  and  fracture  risk assessment  tools  are  helpful  in patients  with  type  2
diabetes  mellitus,  but  underestimate  the absolute  fracture  risk  for a given  score.  New  imaging  modalitiesone mass such  as high  resolution  peripheral  quantitative  computed  tomography  are  promising  for  giving insight  in
the  complex  etiology  underlying  the  fragility  of  the  diabetic  bone,  as they  can  give  more  insight  into  the
microarchitecture  and  geometry  of the  bone.  We  present  an  overview  of  the  contributing  mechanisms
to  the  increased  fracture  risk  and  the usefulness  of imaging  modalities  and  risk  assessment  tools  in
predicting  fracture  risk  in patients  with  type  2 diabetes.
© 2014  Elsevier  Ireland  Ltd.  All  rights  reserved.ontents
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. Introduction
Type 2 diabetes mellitus (T2DM) is a highly prevalent disease,
specially in elderly and obese patients. Since the world popu-
ation is aging and worldwide obesity has nearly doubled since
990 [1,2], the number of T2DM patients is expected to increase
ontinuously. In 2011 it was estimated that 347 million adults
orldwide suffer from diabetes [3]. Ninety percent of all diabetic
atients can be classified as type 2 diabetics [4]. T2DM is charac-
erized by insulin resistance and a relative deficiency of insulin,
eading to a hyperglycemic state. Long term hyperglycemia results
n end organ dysfunction such as neuropathy, retinopathy, car-
iovascular disease and nephropathy, making diabetes one of the
ost important causes of morbidity and mortality in the western
orld.
More recently, an increased fracture risk has been suggested
s another complication of T2DM [5]. Over the past ten years,
he relationship between T2DM and overall, hip, vertebral and
rist fracture risk has been studied extensively [5–23]. For ver-
ebral and wrist fractures it is not clear yet whether fracture
isk is higher than or comparable to fracture risk in nondiabetic
ubjects, but hip and overall fracture risk seem to be evidently
ncreased in T2DM patients (an overview of the literature pub-
ished in the past ten years is presented in Tables 1–4). Fracture
isk seems only to be increased in patients with already estab-
ished T2DM, while patients with newly diagnosed T2DM or with
n impaired glucose tolerance or impaired fasting glucose have
 fracture risk lower than or comparable to nondiabetic subjects
9,13,16].
In the general population, dual energy X-ray absorptiometry
DXA) is the most commonly used imaging modality to diagnose
ubjects with osteopenia and osteoporosis and therefore to iden-
ify subjects with an increased fracture risk. In T2DM patients, bone
ineral density (BMD), as measured with DXA, seems to be normal
o elevated [17]. As fracture risk in these patients is higher than
ould be expected based on their BMD  score, other skeletal and
xtra-skeletal factors should play a role in the increased fracture
isk in T2DM.
In this overview we discuss the possible mechanisms leading
o the increased fracture risk and the usefulness of current and
ew imaging modalities and risk assessment strategies in T2DM
atients.
. Mechanisms leading to the increased fracture risk
In general, the mechanisms leading to fractures can be cate-
orized in four groups: 1. An increased falling frequency; 2. Bone
ragility; 3. A combination of both an increased falling frequency
nd bone fragility; and 4. Neither an increased falling frequency
or fragile bones. In T2DM patients, the increased fracture risk
artly remains after adjusting for their increased falling frequency,
hereby indicating that the increased fracture risk in T2DM patients . . . . .  . . .  . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . .  .  . . .  .  .  .  . . . . . . . . . .  271
is probably due to a combination of both an increased falling fre-
quency and bone fragility (Tables 1–4). Below we  will discuss
some of the mechanisms that lead to an increased falling fre-
quency and factors that cause bone fragility in T2DM patients
(see Fig. 1).
2.1. Increased falling frequency
The prevalence of fall incidents is increased in older T2DM
patients compared to older adults without diabetes [7,24], whereby
T2DM females report more falling incidents than their male coun-
terparts [25]. An increased falling frequency can be observed in both
home dwelling T2DM subjects and T2DM subjects living in nursing
homes [26]. Younger T2DM patients have a fall frequency compa-
rable to healthy subjects, but because of a worse performance in a
timed up and go test (a functional mobility test) when compared
to nondiabetic subjects, there fall risk seems to be increased [27].
T2DM patients who have reported a fall in the previous year, are
also more likely to have had a prior fracture [28].
Diabetic neuropathy, visual impairment due to diabetic
retinopathy, vestibular dysfunction, cognitive impairment and
muscle weakness of the lower limbs are common complications of
diabetes mellitus, especially in case of longstanding and/or poorly
regulated T2DM. All of these complications are associated with an
increased risk of falling [24,28–33].
Neuropathy leads to sensory, motor and autonomic dysfunc-
tion and hence to neuropathic pain, balance problems, orthostatic
hypotension and great variability in step length and step velocity
[29,31,34–36], which are all factors associated with falling. Because
of neuromuscular impairment, T2DM patients are predisposed to
severe falls and to falls to the side, which are both risk factors for
hip fractures [37,38]. Cognitive impairment is associated with a
decline in walking speed and in gait abnormalities as well [24,39],
and could therefore increase the risk of falls in T2DM patients.
Orthostatic hypotension and orthostatic complaints are more
common T2DM patients when compared to subjects without dia-
betes [36,40]. No association between an increased risk of falls and
orthostatic hypotension in T2DM patients is found, but the pres-
ence of orthostatic complaints is associated with an increased risk
of falls, even in patients without established orthostatic hypoten-
sion [36]. A strong relationship between orthostatic complaints
and initial hypotension (within 15 s after standing up) has been
described [41], indicating that the association between orthostatic
complaints and falls is probably due to early orthostatic hypoten-
sion.
The number of prescribed medications was  also reported to be
related to fall risk [24,31,42]. The use of four or more prescribed
medications was  associated with an increased fall risk [42]. As
T2DM patients take nine medications on average (seven without
their antidiabetic drugs) compared to an average of four prescrip-
tions in nondiabetic subjects [24], polypharmacy could be another
contributing factor to the increased fall risk in T2DM patients.
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Table  1
Hip fracture risk in diabetic patients compared to healthy subjects.
Reference Study
design





de Liefde et al.
(2004) [9]
Cohort Both 778 (424 newly
diagnosed, 354
treated)








Ahmed  et al. (2005)
[13]
Cohort Both 373 (175 ♂, 198 ♀) – 26,704 (12,639♂, 14,065 ♀) Adjusted RR
a ♂: 1.63
(0.59–4.5)





Cohort ♀ 74 – 1058 RR 0.54 (0.20–1.49) –
Bonds et al. (2006)
[8]
Cohort ♀ 5285 – 88,120 Adjusted RRb: 1.46
(1.17–1.83)
–
Dobnig et al. (2006)
[22]





Cohort ♀ 8348 – 101,343 Adjusted RRf 2.2
(1.8–2.7)
–
Leslie et al. (2007)
[17]





– 236,682 RR newly diagnosed:
0.83 (0.75–0.92)
RR short term: 1.13
(1.00–1.28)
RR long term: 1.40
(1.28–1.53)
–
Chen  et al. (2008)
[14]
Cohort Both 484,787 – 485,034 ♂: 1.28 (1.21–1.34)♀: 1.72 (1.66–1.78) –
Hothersall et al.
(2014) [23]
Cohort Both 180,841 – 3.66 million Adjustede IRR ♂: 0.97
(0.92–1.02)




Cohort Both 197,412 (100,322♂, 97,090 ♀) – 401,400(202,875 ♂,
198,525 ♀)
♂: 1.18 (1.12–1.24)♀: 1.11 (1.08–1.115) –
Melton et al. (2008)
[7]
Cohort Both 1964 – – SIR overall: 1.1
(0.9–1.4)












Both – – – RR 1.38 (1.25–1.53) –
a Adjusted for age, BMI, smoking, mean blood pressure, HDL and triglycerides.
b Adjusted for ethnicity, weight, height, time-dependent history of falls, previous fracture, history of osteoporosis, trouble seeing at baseline, alcohol or tobacco use, calcium
and  vitamin D intake, exercise, bisphosphonate, estrogen, steroid, insulin, selective estrogen receptor modulator or thyroid hormone use.
c Adjusted for age, weight and calcaneal bone mass.
d Adjusted for age, gender, BMI, smoking, serum creatinine, visual acuity, falling frequency and lower limb disability.
e Adjusted for age, calendar year and Scottish Index of Multiple Deprivation.
f Adjusted for age, BMI, physical activity, menopausal status, estrogen use, smoking, daily intake of calcium, vitamin D and protein.
g Adjusted for use of antidiabetic drugs, prior fracture, corticosteroid use, use of anti-epileptic drugs, use of diuretics, use of anxiolytics and sedatives, use of neuroleptics,
use  of antidepressants, alcoholism, use of statins and non-statin cholesterol-lowering drugs, use of antihypertensives, myocardial infarction, stroke, number of bed days in
1999,  number of contacts to GP or specialists in 1999, working or not, income, living with another person vs living alone.
HR,  hazard ratio; IGT, impaired glucose tolerance; IRR, incidence risk ratio; NDM, nondiabetic subjects; OR, odds ratio; RR, relative risk; SIR, standardized incidence ratio;
T2DM,  Type 2 diabetes mellitus.
Table 2
Vertebral fracture risk in diabetic patients compared to healthy subjects.
Reference Study design Sex N T2DM N NDM Result T2DM vs NDM (95% CI)
Gerdhem et al. (2005) [15] Cohort ♀ 74 1058 RR 0.52 (0.19–1.42)
Bonds  et al. (2006) [8] Cohort ♀ 5285 88,120 Adjusted RRa: 1.27 (1.00–1.61)
Melton et al. (2008) [7] Cohort Both 1964 – SIR 2.8 (2.4–3.2)
Yamatoto et al. (2009) [20] Cohort Both 298 (161 ♂, 137 ♀) 754 (132 ♂, 622 ♀) OR ♂: 4.73 (2.19–10.20), OR ♀: 1.86 (1.11–3.12)
Chung et al. (2013) [21] Cross-sectional ♀ 2239 – OR: 1.03 per 1 year (1.02–1.04), Adjusted RRb: 2.5
Vestergaard et al. (2005) [5] Case–control Both 9598 484,657 Adjusted ORc: 1.34 (0.97–1.86)
Vestergaard et al. (2007) [12] Meta-analysis Both 10,720 494,516 RR: 0.93 (0.63–1.37)
a Adjusted for ethnicity, weight, height, time-dependent history of falls, previous fracture, history of osteoporosis, trouble seeing at baseline, alcohol or tobacco use, calcium
and  vitamin D intake, exercise, bisphosphonate, estrogen, steroid, insulin, selective estrogen receptor modulator or thyroid hormone use.
b Adjusted for age, BMD.
c Adjusted for use of antidiabetic drugs, prior fracture, corticosteroid use, use of anti-epileptic drugs, use of diuretics, use of anxiolytics and sedatives, use of neuroleptics,
use  of antidepressants, alcoholism, use of statins and non-statin cholesterol-lowering drugs, use of antihypertensives, myocardial infarction, stroke, number of bed days in
1999,  number of contacts to GP or specialists in 1999, working or not, income, living with another person vs living alone.
NDM, nondiabetic subjects; OR, odds ratio; RR, relative risk; SIR, standardized incidence ratio; T2DM, Type 2 diabetes mellitus.
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Table 3
Wrist fracture risk in diabetic patients compared to healthy subjects.





de Liefde et al.
(2004) [9]
Cohort Both 778 (424 newly
diagnosed, 354
treated)











Cohort ♀ 74 – 1058 RR: 0.62 (0.33–1.16) –
Bonds et al. (2006)
[8]
Cohort ♀ 5285 – 88,120 Adjusted RRb: 1.02
(0.85–1.22)
–
Melton et al. (2008)
[7]
Cohort Both 1964 – – SIR: 1.2 (0.9–1.5) –
Vestergaard et al.
(2005) [5]





Meta-analysis Both 10,720 – 494,516 RR 1.19 (1.01–1.41) –
a Adjusted for ethnicity, weight, height, time-dependent history of falls, previous fracture, history of osteoporosis, trouble seeing at baseline, alcohol or tobacco use, calcium
and  vitamin D intake, exercise, bisphosphonate, estrogen, steroid, insulin, selective estrogen receptor modulator or thyroid hormone use.
b Adjusted for age, gender, BMI, smoking, serum creatinine, visual acuity, falling frequency and lower limb disability.
c Adjusted for use of antidiabetic drugs, prior fracture, corticosteroid use, use of anti-epileptic drugs, use of diuretics, use of anxiolytics and sedatives, use of neuroleptics,















999,  number of contacts to GP or specialists in 1999, working or not, income, livin
R,  hazard ratio; IGT, impaired glucose tolerance; NDM, nondiabetic subjects; OR
ellitus.
.2. Bone fragility
Bone strength is a result of many factors, including bone mass
bone quantity) and bone quality [43]. A decrease in bone mass,
 diminished bone quality and/or changes in bone geometry can
herefore result in bone fragility.
.2.1. Bone mass
There is extensive literature available about areal bone mineral
ensity (aBMD) measurements using DXA in T2DM patients. Two
ecent meta-analyses as well as two recent systematic reviews con-
luded that BMD  in T2DM patients seems to be normal to elevated
hen compared to nondiabetic subjects, even after adjustment for
ody mass index (BMI) [17,44–46].
With quantitative ultrasound, the estimated bone mineral den-
ity (eBMD) can be calculated. eBMD is derived from the stiffness
Incr eased fract ure  ri sk in 
Incr eas ed bone fragi lty  
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Fig. 1. Underlying mechanisms of the increased fracture risk in another person vs living alone.
 ratio; RR, relative risk; SIR, standardized incidence ratio; T2DM, Type 2 diabetes
index, which in turn is derived from both the speed of sound
and the broadband ultrasound attenuation [47]. Using quantitative
ultrasound, an increase in eBMD was observed in T2DM patients
compared to nondiabetic subjects [28].
High resolution peripheral quantitative computed tomogra-
phy (HR-pQCT) is a new non-invasive three-dimensional imaging
modality. It has the ability to measure volumetric bone mineral
density (vBMD), which is, in comparison to aBMD, a more accurate
presentation of bone mineralization [48]. vBMD of the trabecular
bone of both the radius and tibia is significantly higher in T2DM
patients when compared to nondiabetic subjects [49,50], which is
in agreement with the increased values of aBMD and eBMD.Little is known about longitudinal changes in BMD  in T2DM
patients. Some studies showed an increased bone loss at the
hip in type 2 diabetic women despite an elevated baseline BMD
[12,51,52], but no difference in bone loss rates could be found in
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de Liefde et al. (2004) [9] Cohort Both 778 (424 newly
diagnosed, 354
treated)
– 1543 4320 Adjusted HRc newly
diagnosed: 0.82 (0.56–1.18)





Ahmed  et al. (2005) [13] Cohort Both 373 (175 ♂, 198 ♀) – – 26,704 (12,639♂, 14,065 ♀) Adjusted RR
a ♂: 1.21
(0.6–2.47)
Adjusted RR ♀: 1.08
(0.7–1.67)
– –
Gerdhem et al. (2005) [15] Cohort ♀ 74 – – 1058 RR: 0.83 (0.52–1.33) – –




Bonds  et al. (2006) [8] Cohort ♀ 5285 – – 88,120 Adjusted RRb: 1.20 (1.11–1.30) – –





– – 236,682 RR newly diagnosed: 0.91
(0.86–0.95)
RR short term: 1.00 (0.93–1.07)
RR long term: 1.15 (1.09–1.22)
– –
Melton  et al. (2008) [7] Cohort Both 1964 – – – SIR 1.3 (1.2–1.4) – –
Khalil  et al., 2011 [10] Cohort ♀ 117 – – 2054 Adjusted RRd: 1.81 (1.05–3.12) – –
Vestergaard et al., 2005 [5] Case–control Both 9598 – – 484,657 Adjusted ORf: 1.19 (1.11–1.27) – –
Vestergaard et al., 2007
[12]
Meta-analysis Both 10,720 – – 494,516 RR: 0.96 (0.57–1.61) – –
a Adjusted for age, BMI, smoking, mean blood pressure, HDL and triglycerides.
b Adjusted for ethnicity, weight, height, time-dependent history of falls, previous fracture, history of osteoporosis, trouble seeing at baseline, alcohol or tobacco use, calcium and vitamin D intake, exercise, bisphosphonate,
estrogen, steroid, insulin, selective estrogen receptor modulator or thyroid hormone use.
c Adjusted for age, gender, BMI, smoking, serum creatinine, visual acuity, falling frequency and lower limb disability.
d Adjusted for past history of fractures, age, weight, smoking, lifestyle (alcohol drinks/day, physical activity, clinic, health and economic status), vitamin D, calcium use, baseline hip BMD, ethnicity.
e Adjusted for sex, race, age, site, BMD.
f Adjusted for use of antidiabetic drugs, prior fracture, corticosteroid use, use of anti-epileptic drugs, use of diuretics, use of anxiolytics and sedatives, use of neuroleptics, use of antidepressants, alcoholism, use of statins and
non-statin  cholesterol-lowering drugs, use of antihypertensives, myocardial infarction, stroke, number of bed days in 1999, number of contacts to GP or specialists in 1999, working or not, income, living with another person vs
living  alone.
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2DM men  or black women [12,52]. This suggests that there might
e racial or gender differences in bone metabolism, which could
e due to differences in body composition and differences in sex
ormones (e.g. postmenopausal status in most studied women).
It is not completely clear whether duration of T2DM is associated
ith BMD. Some studies did not found an association between BMD
nd duration of the disease [53–55], but others did show a nega-
ive association [56–59]. As the studies that were not able to find
n association between BMD  and duration of the disease did not
nclude any patients with a very long duration (>20 years) of the dis-
ase, the lack between an association between BMD  and duration
f the disease in this studies could be due to population bias.
The influence of glucose control (defined as mean glycated
emoglobin (HbA1c)) on BMD  is also not completely understood, as
he results from the performed studies vary from a positive [22,44]
o a negative [60,61] correlation. Most studies however did not find
 correlation at all between HbA1c and BMD  [53–55,58,59].
.2.2. Bone quality
Bone quality is defined as the totality of features and charac-
eristics that influence a bone’s ability to resist fracture [62] and
s determined by bone (micro)architecture and by the material
roperties such as bone mineralization and the quality of collagen,
hich are being influenced by bone turnover and accumulation of
icrodamage [63].
In diabetic patients, bone remodeling appears to be impaired
s both markers of bone formation and markers of bone resorp-
ion are decreased when compared to healthy subjects [64–67]. The
nfluence of glycemic control on bone turnover in T2DM patients
s not clear, as the effect of glycemic control in different studies
aries from a decrease to an increase in bone turnover markers
22,68–73].
For normal osteogenesis, the Wnt/-catenin pathyway is essen-
ial [74]. Serum sclerostin is an inhibitor of the Wnt/-catenin
ignaling pathway and is therefore an inhibitor of bone formation.
clerostin was found to be significantly increased in T2DM patients
hen compared to people without T2DM [66,67,75], and could thus
e the cause of the decreased bone formation markers. Sclerostin
s positively correlated with vertebral fractures in T2DM patients
66] and therapy with sclerostin-neutralizing monoclonal antibod-
es fully reverses the negative effect of T2DM on bone mass and
trength in rats [76].
The quality of bone collagen can be impaired by accumulation of
dvanced glycation end products (AGEs). AGEs are a highly stable
ross-linked product and are formed by a series of non-enzymatic
eactions between glucose and proteins [77,78]. The level of AGE
entosidine was higher in T2DM patients [79], and it was positively
orrelated with incident clinical and prevalent vertebral fractures
n T2DM patients, while no association between pentosidine and
racture risk could be found in nondiabetic subjects [78,79].
Elevated blood glucose levels lead to hypercalcuria [80],
nd could therefore influence bone mineralization. Despite the
ncreased calcium loss due to renal leakage, serum levels of
arathyroid hormone (PTH) seem to be lower in diabetic patients
22,66]. This state of functional hypoparathyroidism could play a
ole in the pathogenesis of the above described state of low bone
urnover in diabetic subjects, as a negative correlation between
clerostin and PTH has been noticed in several studies [66,75,81].
he prevalence of hypovitaminosis D in type 2 diabetic patients is
igh [82], but serum levels of vitamin D do not differ significantly
etween diabetic patients and healthy subjects [10,22].
Adiponectin is one the adipocytokines and is secreted from
he adipose tissue [83]. Osteoblasts have been shown to have
diponectin receptors and the proliferation, differentiation and
ineralization of osteoblastic cells are enhanced by adiponectin
84,85]. Adiponectin levels have been shown to be elevated duringtas 79 (2014) 265–274
weight loss and decreased during weight gain [86]. Adiponectin
levels in T2DM patients are inversely correlated with bone mass
[71,87] and positively associated with vertebral fractures in T2DM
men  [87]. The underlying mechanism has not been completely
unraveled.
HR-pQCT can be used to take a close look at trabecular and cor-
tical microarchitecture separately and to calculate bone strength
indices. Up to date, only a few small studies have used HR-
pQCT to examine differences in bone microarchitecture between
T2DM patients and nondiabetic subjects [49,50,72,88,89]. In most
of these studies, there were no significant differences between
HR-pQCT microarchitecture parameters between T2DM patients
and healthy subjects [72,88,89]. Increased cortical porosity was
found in T2DM patients with fragility fractures, when compared
to diabetic patients without fragility fractures [88]. One study
also showed greater cortical porosity between T2DM patients and
control subjects, but after adjustment for fragility fractures, the dif-
ference disappeared [49,88]. No differences were found in bone
strength between T2DM patients and healthy controls when using
HR-pQCT parameters [49,88].
Changes in bone geometry can increase fracture risk due to a
decreased bending strength of a specific bone and/or a decreased
resistance to axial load [90]. Previous research showed that bone
geometry adapts to changes in skeletal loading over time, whereby
an increase in body weight was  associated with an increase in sec-
tion modulus (an index of bending and torsional strength) [91].
These changes in geometry are most probably due to differences in
lean mass and muscle strength and thus a result of muscle loads
on bone [91]. A recent study in obese women showed that a higher
BMI  was associated with lower indices of bone strength relative
to load and that obesity, after adjustment for BMD, was  associated
with an increased fracture risk. This increased risk is probably due
to larger fall impact forces on bone in these patients [92].
In diabetic patients, lean mass was able to predict hip strength
[93]. As T2DM patients are known to have lower skeletal muscle
strength and muscle quality [33], an unfavorable effect on bone
geometry in T2DM patients would be expected. One study using
peripheral quantitative computed tomography indeed showed that
they had lower bone bending strength after adjustment for body
weight, especially in the more cortical regions of the bone [50].
2.2.3. The influence of antidiabetic drugs on bone fragility
The use of thiazolidinediones (TZDs) has been associated with an
increased fracture risk in both T2DM men  and women when com-
pared to non-diabetic patients and to diabetic patients using other
blood glucose lowering drugs. As both rosiglitazone and pioglita-
zone show this increased risk, a class effect of TZDs is suggested
[94–96]. TZDs could have a negative effect on bone quality, since
they suppress the differentiation of mesenchymal stem cells into
osteoblasts in favor of differentiation to adipocytes. In addition, TZD
use is associated with a decrease in BMD  at both the hip and spine,
and after discontinuing the use of TZDs no further decline in BMD
was found [97,98].
Insulin stimulates bone formation [99], hence a direct negative
effect of insulin on bone quality is not to be expected. Insulin use
is associated with an increased fracture risk [6,11,100]. But this
increased fracture risk was  most probably due to an increased risk
of falls because of hypoglycemic events and because insulin is often
only used in patients with diabetes of longer duration and thus in
patients who  are likely to have long term negative hyperglycemic
effects on bone quality [24,31,42].
Metformin is osteogenic in vitro [101] and a small gain in BMD
at the femoral neck and lumbar spine in metformin users has been
noted [97]. Most clinical studies found no positive or negative effect
of metformin on fracture risk [102,103], although one study indeed
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No difference in fracture risk could be found in patients using
ulfonylureas, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-
ike peptide 1 (GLP-1) agonists or sodium-glucose transport protein
 (SGLT2) inhibitors [104–109] as compared to subjects without
2DM. In fact, DDP4 inhibitors and GLP-1 agonists possibly had a
rotective effect on bone due to the increase of circulating levels of
LP-1 and gastric intestinal polypeptide, which are both involved
n the regulation of bone metabolism [107,109,110].
. The usefulness of imaging modalities and fracture risk
ssessment tools
.1. Imaging modalities
DXA is the most commonly used technique for diagnosing osteo-
orosis and osteopenia. These diagnoses are defined as a T-score (a
ubjects aBMD compared to the mean BMD  of a young adult refer-
nce population) of ≤−2.5 and between −1.0 and −2.5 respectively
111]. There is extensive literature available about DXA measure-
ents in T2DM subjects, but less is known about the usefulness
f the BMD  measurements for the determination of fracture risk
n this population. In three small studies, no association between
MD  and the presence of prevalent vertebral fractures was found
n T2DM patients [20,112,113], but a large trial that used the
rospective data from three observational studies found a negative
ssociation between femoral neck T-score and hip and nonspine
racture risk [114]. The ability to predict fracture risk based on T-
core is the same in adults with and without T2DM [114]. However,
racture risk in T2DM patients for a given T-score is higher than
racture risk for the non-diabetic controls [114].
eBMD and calcaneal stiffness as measured with quantitative
ltrasound are both significantly lower in type 2 diabetic patients
ith a prior fracture [28] and can therefore probably be used to
etermine fracture risk. One study however could not find a differ-
nce in speed of sound between type 2 diabetic patients with and
ithout vertebral fractures [113].
Up to date, no studies have investigated the usefulness of HR-
QCT in determining fracture risk.
.2. WHO  fracture risk algorithm (FRAX®)
The fracture risk assessment tool is developed by the World
ealth Organization in 2008 and can be used to predict the 10-
ear risk of a major osteoporotic or hip fracture for a 40–90 year
ld subject. If available, BMD  of the hip can also be entered into the
RAX® algorithm [115].
The fracture risk of T2DM patients for both major osteoporotic
nd hip fractures seems comparable to the fracture risk for nondi-
betic subjects according to the FRAX® algorithm, based on their
linical parameters and femoral neck BMD  [116,117]. When only
linical parameters were used, fracture risk in diabetic subjects cal-
ulated with the FRAX® algorithm is lower than the fracture risk in
 matched group of healthy controls [118].
Although FRAX® scores correlate with hip and nonspine frac-
ures [114,117,118], FRAX® underestimates fracture risk in diabetic
atients because observed fracture rates were higher than pre-
icted when using the FRAX® algorithm [114,116–118]. One study
howed that diabetes status is an independent predictor of hip
nd major osteoporotic fractures after adjustment for the clinical
arameters as used in the FRAX® tool [117]. Another study showed
hat the association of major osteoporotic and hip fracture FRAX
cores were higher when HbA1c and hypoglycemic events were
dded to the algorithm [118]. For hip fracture FRAX scores, the asso-
iation also increases when macrovascular complications in men
nd neuropathy in women was added to the model [118].tas 79 (2014) 265–274 271
Up to date, no studies have used other fracture risk assessment
tools (such as the Garvan Fracture Risk Calculator) to determine
fracture risk in T2DM patients.
4. Conclusion
In this overview we discussed the underlying mechanisms of
the increased fracture risk in T2DM patients and of the usefulness
of fracture risk assessment tools in predicting fracture risk in T2DM
patients.
In T2DM patients, the increased fracture risk can be partly
explained by an increased fall risk due to complications of the
disease such as neuropathy and retinopathy. Although bone mass
seems to be normal to elevated in T2DM patients, bone qual-
ity and thus bone strength is decreased due to changes in bone
(micro)architecture and material properties such as bone mineral-
ization and the quality of collagen when compared to nondiabetic
patients. The use of antidiabetic drugs, especially TZD’s, can also
contribute to the increased fracture risk by decreasing both bone
mass and quality.
DXA and FRAX® can be used to assess fracture risk in T2DM
patients in clinical practice, but it is important to realize that they
both underestimate the absolute fracture risk when compared to
assessment in nondiabetic subjects. For a more accurate risk assess-
ment, it could be useful to add T2DM as an extra risk factor to
the FRAX® tool. HR-pQCT is a promising new imaging modality
because of its ability to get a virtual bone biopsy and to analyze bone
strength in vivo. Therefore would it be interesting to determine its
usefulness in the determination of fracture risk.
Contributors
E.A.C. de Waard, T.A.C.M. van Geel, H.H.C.M. Savelberg, A. Koster,
P.P.M.M. Geusens and J.P.W. van den Bergh all participated in the
planning, writing, correction and finalization of the article.
Competing interest
The authors declare no conflict of interest.
Funding
Research funding from “Stichting de Weijerhorst”.
Provenance and peer review
Commissioned and externally peer reviewed.
References
[1] World Health Organization. Fact sheet ageing; 2012. Available from:
http://www.who.int/ageing/about/facts/en/ [cited 27.02.14].
[2] World Health Organization. Fact sheet obesity; 2013. Available from:
http://www.who.int/mediacentre/factsheets/fs311/en/ [cited 27.02.14].
[3]  Danaei G, Finucane MM,  Lu Y, et al. National, regional, and global trends in
fasting plasma glucose and diabetes prevalence since 1980: systematic anal-
ysis of health examination surveys and epidemiological studies with 370
country-years and 2.7 million participants. Lancet 2011;378(9785):31–40,
http://dx.doi.org/10.1016/s0140-6736(11)60679-x.
[4]  Alberti KG, Zimmet PZ. Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: Diagnosis and
classification of diabetes mellitus provisional report of a WHO
consultation. Diabet Med 1998;15(7):539–53, http://dx.doi.org/
.
[5] Janghorbani M,  Van Dam RM,  Willett WC,  Hu FB. Systematic review of
type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol
2007;166(5):495–505, http://dx.doi.org/10.1093/aje/kwm106.
2 aturi72 E.A.C. de Waard et al. / M
[6] Ahmed LA, Joakimsen RM,  Berntsen GK, Fonnebo V, Schirmer H. Diabetes
mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos
Int 2006;17(4):495–500, http://dx.doi.org/10.1007/s00198-005-0013-x.
[7]  Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in
women  with type 2 diabetes: the Women’s Health Initiative
Observational Study. J Clin Endocrinol Metab 2006;91(9):3404–10,
http://dx.doi.org/10.1210/jc.2006-0614.
[8] Chen HF, Ho CA, Li CY. Increased risks of hip fracture in diabetic patients
of  Taiwan: a population-based study. Diabetes Care 2008;31(1):75–80,
http://dx.doi.org/10.2337/dc07-1072.
[9] de Liefde II, van der Klift M,  de Laet CE, van Daele PL, Hofman A,
Pols HA. Bone mineral density and fracture risk in type-2 diabetes
mellitus: the Rotterdam Study. Osteoporos Int 2005;16(12):1713–20,
http://dx.doi.org/10.1007/s00198-005-1909-1.
[10] Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and
decreased bone turnover, but no evident alteration of fracture susceptibility in
elderly women with diabetes mellitus. Osteoporos Int 2005;16(12):1506–12,
http://dx.doi.org/10.1007/s00198-005-1877-5.
[11] Janghorbani M,  Feskanich D, Willett WC,  Hu F. Prospective study of dia-
betes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care
2006;29(7):1573–8, http://dx.doi.org/10.2337/dc06-0440.
[12] Khalil N, Sutton-Tyrrell K, Strotmeyer ES, et al. Menopausal bone changes
and incident fractures in diabetic women: a cohort study. Osteoporos Int
2011;22(5):1367–76, http://dx.doi.org/10.1007/s00198-010-1357-4.
[13] Leslie WD,  Lix LM,  Prior HJ, Derksen S, Metge C, O’Neil J. Biphasic frac-
ture risk in diabetes: a population-based study. Bone 2007;40(6):1595–601,
http://dx.doi.org/10.1016/j.bone.2007.02.021.
[14] Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in
older individuals with diabetes: a population-based study. Diabetes Care
2007;30(4):835–41, http://dx.doi.org/10.2337/dc06-1851.
[15] Melton LJ, 3rd, Leibson CL, Achenbach SJ, Therneau TM,  Khosla S. Fracture
risk in type 2 diabetes: update of a population-based study. J Bone Miner Res
2008;23(8):1334–42, http://dx.doi.org/10.1359/jbmr.080323.
[16] Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk
with diabetes mellitus and impaired fasting glucose in older white and black
adults: the health, aging, and body composition study. Arch Intern Med
2005;165(14):1612–7, http://dx.doi.org/10.1001/archinte.165.14.1612.
[17] Vestergaard P. Discrepancies in bone mineral density and fracture risk in
patients with type 1 and type 2 diabetes – a meta-analysis. Osteoporos Int
2007;18(4):427–44, http://dx.doi.org/10.1007/s00198-006-0253-4.
[18] Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients
with diabetes mellitus, and the impact of insulin and oral antidia-
betic medication on relative fracture risk. Diabetologia 2005;48(7):1292–9,
http://dx.doi.org/10.1007/s00125-005-1786-3.
[19] Viegas M,  Costa C, Lopes A, Griz L, Medeiro MA,  Bandeira F. Prevalence
of  osteoporosis and vertebral fractures in postmenopausal women with
type 2 diabetes mellitus and their relationship with duration of the dis-
ease and chronic complications. J Diabetes Complic 2011;25(4):216–21,
http://dx.doi.org/10.1016/j.jdiacomp.2011.02.004.
[20] Yamamoto M,  Yamaguchi T, Yamauchi M,  Kaji H, Sugimoto T. Dia-
betic patients have an increased risk of vertebral fractures independent
of BMD  or diabetic complications. J Bone Miner Res 2009;24(4):702–9,
http://dx.doi.org/10.1359/jbmr.081207.
[21] Chung DJ, Choi HJ, Chung YS, Lim SK, Yang SO, Shin CS. The preva-
lence and risk factors of vertebral fractures in Korean patients
with type 2 diabetes. J Bone Miner Metab 2013;31(2):161–8,
http://dx.doi.org/10.1007/s00774-012-0398-5.
[22] Dobnig H, Piswanger-Solkner JC, Roth M,  et al. Type 2 diabetes
mellitus in nursing home patients: effects on bone turnover, bone
mass, and fracture risk. J Clin Endocrinol Metab 2006;91(9):3355–63,
http://dx.doi.org/10.1210/jc.2006-0460.
[23] Hothersall EJ, Livingstone SJ, Looker HC, et al. Contemporary risk of hip frac-
ture  in type 1 and type 2 diabetes: a national registry study from Scotland. J
Bone Miner Res 2014;29(5):1054–60, http://dx.doi.org/10.1002/jbmr.2118.
[24]  Roman de Mettelinge T, Cambier D, Calders P, Van Den Noortgate N, Del-
baere K. Understanding the relationship between type 2 diabetes mellitus and
falls in older adults: a prospective cohort study. PLOS ONE 2013;8(6):e67055,
http://dx.doi.org/10.1371/journal.pone.0067055.
[25] Tilling LM,  Darawil K, Britton M. Falls as a complication of dia-
betes mellitus in older people. J Diabetes Complic 2006;20(3):158–62,
http://dx.doi.org/10.1016/j.jdiacomp.2005.06.004.
[26] Maurer MS,  Burcham J, Cheng H. Diabetes mellitus is associated
with an increased risk of falls in elderly residents of a long-
term care facility. J Gerontol Ser A Biol Sci Med Sci 2005;60(9):
1157–62.
[27] Oliveira PP, Fachin SM,  Tozatti J, Ferreira MC,  Marinheiro LP. Comparative
analysis of risk for falls in patients with and without type 2 diabetes mellitus.
Rev Assoc Med  Bras 2012;58(2):234–9.[28] Patel S, Hyer S, Tweed K, et al. Risk factors for fractures and falls in older
women  with type 2 diabetes mellitus. Calcif Tissue Int 2008;82(2):87–91,
http://dx.doi.org/10.1007/s00223-007-9082-5.tas 79 (2014) 265–274
[29] Macgilchrist C, Paul L, Ellis BM,  Howe TE, Kennon B, Godwin J. Lower-
limb risk factors for falls in people with diabetes mellitus. Diabet Med
2010;27(2):162–8, http://dx.doi.org/10.1111/j.1464-5491.2009.02914.x.
[30] Agrawal Y, Carey JP, Della Santina CC, Schubert MC,  Minor LB. Dia-
betes, vestibular dysfunction, and falls: analyses from the National Health
and Nutrition Examination Survey. Otol Neurotol 2010;31(9):1445–50,
http://dx.doi.org/10.1097/MAO.0b013e3181f2f035.
[31] Pijpers E, Ferreira I, de Jongh RT, et al. Older individuals with diabetes have
an  increased risk of recurrent falls: analysis of potential mediating factors:
the  Longitudinal Ageing Study Amsterdam. Age Ageing 2012;41(3):358–65,
http://dx.doi.org/10.1093/ageing/afr145.
[32] IJzerman TH, Schaper NC, Melai T, Meijer K, Willems PJ, Savelberg HH.
Lower extremity muscle strength is reduced in people with type 2 diabetes,
with and without polyneuropathy, and is associated with impaired mobil-
ity and reduced quality of life. Diabetes Res Clin Pract 2012;95(3):345–51,
http://dx.doi.org/10.1016/j.diabres.2011.10.026.
[33] Park SW,  Goodpaster BH, Strotmeyer ES, et al. Decreased muscle
strength and quality in older adults with type 2 diabetes: the health,
aging, and body composition study. Diabetes 2006;55(6):1813–8,
http://dx.doi.org/10.2337/db05-1183.
[34] Lalli P, Chan A, Garven A, et al. Increased gait variability in diabetes melli-
tus  patients with neuropathic pain. J Diabetes Complic 2013;27(3):248–54,
http://dx.doi.org/10.1016/j.jdiacomp.2012.10.013.
[35] Zochodne DW.  Diabetic polyneuropathy: an update. Curr Opin Neurol
2008;21(5):527–33, http://dx.doi.org/10.1097/WCO.0b013e32830b84cb.
[36]  van Hateren KJ, Kleefstra N, Blanker MH,  et al. Orthostatic hypotension, dia-
betes, and falling in older patients: a cross-sectional study. Brit J Gen Pract
2012;62(603):e696–702, http://dx.doi.org/10.3399/bjgp12X656838.
[37] Greenspan SL, Myers ER, Kiel DP, Parker RA, Hayes WC,  Resnick NM.  Fall direc-
tion,  bone mineral density, and function: risk factors for hip fracture in frail
nursing home elderly. Am J Med  1998;104(6):539–45.
[38] Greenspan SL, Myers ER, Maitland LA, Resnick NM,  Hayes WC.  Fall severity
and bone mineral density as risk factors for hip fracture in ambulatory elderly.
JAMA 1994;271(2):128–33.
[39] Lee CG, Schwartz AV, Yaffe K, Hillier TA, LeBlanc ES, Cawthon PM.
Changes in physical performance in older women according to presence
and treatment of diabetes mellitus. J Am Geriatr Soc 2013;61(11):1872–8,
http://dx.doi.org/10.1111/jgs.12502.
[40] Wu JS, Yang YC, Lu FH, Wu CH, Wang RH, Chang CJ. Population-based
study on the prevalence and risk factors of orthostatic hypotension in
subjects with pre-diabetes and diabetes. Diabetes Care 2009;32(1):69–74,
http://dx.doi.org/10.2337/dc08-1389.
[41] Romero-Ortuno R, Cogan L, Foran T, Kenny RA, Fan CW.  Continuous noninva-
sive orthostatic blood pressure measurements and their relationship with
orthostatic intolerance, falls, and frailty in older people. J Am Geriatr Soc
2011;59(4):655–65, http://dx.doi.org/10.1111/j.1532-5415.2011.03352.x.
[42]  Huang ES, Karter AJ, Danielson KK, Warton EM,  Ahmed AT. The asso-
ciation between the number of prescription medications and incident
falls  in a multi-ethnic population of adult type-2 diabetes patients:
the  diabetes and aging study. J Gen Intern Med  2010;25(2):141–6,
http://dx.doi.org/10.1007/s11606-009-1179-2.
[43] Tranquilli Leali P, Doria C, Zachos A, Ruggiu A, Milia F, Barca F. Bone
fragility: current reviews and clinical features. Clin Cases Miner Bone Metab
2009;6(2):109–13.
[44] Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type
2  diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol
2012;27(5):319–32, http://dx.doi.org/10.1007/s10654-012-9674-x.
[45]  Abdulameer SA, Sulaiman SA, Hassali MA,  Subramaniam K, Sahib
MN.  Osteoporosis and type 2 diabetes mellitus: what do we know,
and what we can do? Patient Prefer Adherence 2012;6:435–48,
http://dx.doi.org/10.2147/PPA.S32745.
[46] Gorman E, Chudyk AM,  Madden KM,  Ashe MC.  Bone health and type 2
diabetes mellitus: a systematic review. Physiother Can 2011;63(1):8–20,
http://dx.doi.org/10.3138/ptc.2010-23bh.
[47] Chin KY, Ima-Nirwana S. Calcaneal quantitative ultrasound as a determinant
of bone health status: what properties of bone does it reflect? Int J Med  Sci
2013;10(12):1778–83, http://dx.doi.org/10.7150/ijms.6765.
[48] MacNeil JA, Boyd SK. Accuracy of high-resolution periph-
eral quantitative computed tomography for measurement
of  bone quality. Med  Eng Phys 2007;29(10):1096–105,
http://dx.doi.org/10.1016/j.medengphy.2006.11.002.
[49] Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral
quantitative computed tomographic imaging of cortical and trabecular bone
microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol
Metab 2010;95(11):5045–55, http://dx.doi.org/10.1210/jc.2010-0226.
[50]  Petit MA,  Paudel ML,  Taylor BC, et al. Bone mass and strength in older men
with type 2 diabetes: the Osteoporotic Fractures in Men  Study. J Bone Miner
Res  2010;25(2):285–91, http://dx.doi.org/10.1359/jbmr.090725.[51] Schwartz AV, Ewing SK, Porzig AM,  et al. Diabetes and change in bone min-
eral density at the hip, calcaneus, spine, and radius in older women. Front
Endocrinol 2013;4:62, http://dx.doi.org/10.3389/fendo.2013.00062.
aturiE.A.C. de Waard et al. / M
[52] Hamilton EJ, Rakic V, Davis WA,  et al. A five-year prospective
study of bone mineral density in men  and women with diabetes:
the Fremantle Diabetes Study. Acta Diabetol 2012;49(2):153–8,
http://dx.doi.org/10.1007/s00592-011-0324-7.
[53] Bridges MJ,  Moochhala SH, Barbour J, Kelly CA. Influence of diabetes on
peripheral bone mineral density in men: a controlled study. Acta Diabetol
2005;42(2):82–6, http://dx.doi.org/10.1007/s00592-005-0183-1.
[54] Tao B, Liu JM,  Zhao HY, et al. Differences between measurements of bone
mineral densities by quantitative ultrasound and dual-energy X-ray absorp-
tiometry in type 2 diabetic postmenopausal women. J Clin Endocrinol Metab
2008;93(5):1670–5, http://dx.doi.org/10.1210/jc.2007-1760.
[55] Vasilkova O, Mokhort T, Sanec I, Sharshakova T, Hayashida N, Takamura
N.  Testosterone is an independent determinant of bone mineral density in
men  with type 2 diabetes mellitus. Clin Chem Lab Med 2011;49(1):99–103,
http://dx.doi.org/10.1515/cclm.2011.016.
[56] Hadjidakis DI, Androulakis II, Mylonakis AM,  et al. Diabetes in post-
menopause: different influence on bone mass according to age and
disease duration. Exp Clin Endocrinol Diabetes 2009;117(5):199–204,
http://dx.doi.org/10.1055/s-2008-1080921.
[57] Di Somma  C, Rubino M,  Faggiano A, et al. Spinal deformity index
in  patients with type 2 diabetes. Endocrine 2013;43(3):651–8,
http://dx.doi.org/10.1007/s12020-012-9848-z.
[58] Anaforoglu I, Nar-Demirer A, Bascil-Tutuncu N, Ertorer ME. Prevalence
of  osteoporosis and factors affecting bone mineral density among post-
menopausal Turkish women with type 2 diabetes. J Diabetes Complic
2009;23(1):12–7, http://dx.doi.org/10.1016/j.jdiacomp.2007.06.004.
[59] Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated indepen-
dently of body composition with BMD  and bone volume in older white and
black men  and women: the Health, Aging, and Body Composition Study. J Bone
Miner Res 2004;19(7):1084–91, http://dx.doi.org/10.1359/jbmr.040311.
[60] Majima T, Komatsu Y, Yamada T, et al. Decreased bone mineral density
at the distal radius, but not at the lumbar spine or the femoral neck,
in  Japanese type 2 diabetic patients. Osteoporos Int 2005;16(8):907–13,
http://dx.doi.org/10.1007/s00198-004-1786-z.
[61] Zhou Y, Li Y, Zhang D, Wang J, Yang H. Prevalence and predictors
of  osteopenia and osteoporosis in postmenopausal Chinese women
with type 2 diabetes. Diabetes Res Clin Pract 2010;90(3):261–9,
http://dx.doi.org/10.1016/j.diabres.2010.09.013.
[62] Bouxsein ML.  Mechanisms of osteoporosis therapy: a bone strength perspec-
tive. Clin Cornerstone 2003;(Suppl. 2):S13–21.
[63] Donnelly E. Methods for assessing bone quality: a review. Clin Orthop
2011;469(8):2128–38, http://dx.doi.org/10.1007/s11999-010-1702-0.
[64] Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, Sozen T. Evaluation of bone
metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl
Med Assoc 2006;98(10):1598–604.
[65] Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with
inhibition of the Wnt/beta-catenin signaling and reduced bone turnover
in  type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97(10):3744–50,
http://dx.doi.org/10.1210/jc.2012-1901.
[66] Ardawi MS,  Akhbar DH, Alshaikh A, et al. Increased serum sclerostin
and decreased serum IGF-1 are associated with vertebral fractures among
postmenopausal women  with type-2 diabetes. Bone 2013;56(2):355–62,
http://dx.doi.org/10.1016/j.bone.2013.06.029.
[67] Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and
bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab
2012;97(5):1737–44, http://dx.doi.org/10.1210/jc.2011-2958.
[68] Capoglu I, Ozkan A, Ozkan B, Umudum Z. Bone turnover mark-
ers in patients with type 2 diabetes and their correlation with
glycosylated haemoglobin levels. J Int Med  Res 2008;36(6):
1392–8.
[69] Kanazawa I, Yamaguchi T, Yamauchi M,  et al. Adiponectin is asso-
ciated with changes in bone markers during glycemic control in
type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94(8):3031–7,
http://dx.doi.org/10.1210/jc.2008-2187.
[70] Kanazawa I, Yamaguchi T, Yamamoto M,  Yamauchi M,  Yano S, Sugimoto T.
Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for
the  presence of vertebral fractures in men  with type 2 diabetes. Calcif Tissue
Int  2009;85(3):228–34, http://dx.doi.org/10.1007/s00223-009-9272-4.
[71] Miazgowski T, Noworyta-Zietara M,  Safranow K, Ziemak J, Widecka
K.  Serum adiponectin, bone mineral density and bone turnover
markers in post-menopausal women with newly diagnosed Type
2  diabetes: a 12-month follow-up. Diabet Med 2012;29(1):62–9,
http://dx.doi.org/10.1111/j.1464-5491.2011.03381.x.
[72] Shu A, Yin MT, Stein E, et al. Bone structure and turnover in
type 2 diabetes mellitus. Osteoporos Int 2012;23(2):635–41,
http://dx.doi.org/10.1007/s00198-011-1595-0.
[73] Rasul S, Ilhan A, Wagner L, Luger A, Kautzky-Willer A. Diabetic polyneuro-
pathy relates to bone metabolism and markers of bone turnover in elderly
patients with type 2 diabetes: greater effects in male patients. Gend Med
2012;9(3):187–96, http://dx.doi.org/10.1016/j.genm.2012.03.004.
[74] Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling
in  mesenchymal progenitors controls osteoblast and chondrocytetas 79 (2014) 265–274 273
differentiation during vertebrate skeletogenesis. Dev Cell 2005;8(5):739–50,
http://dx.doi.org/10.1016/j.devcel.2005.03.016.
[75] Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, et al. Circu-
lating levels of sclerostin are increased in patients with type 2
diabetes mellitus. J Clin Endocrinol Metab 2012;97(1):234–41,
http://dx.doi.org/10.1210/jc.2011-2186.
[76] Hamann C, Rauner M,  Hohna Y, et al. Sclerostin antibody treatment
improves bone mass, bone strength, and bone defect regeneration in
rats with type 2 diabetes mellitus. J Bone Miner Res 2013;28(3):627–38,
http://dx.doi.org/10.1002/jbmr.1803.
[77] Goh SY, Cooper ME. Clinical review: the role of advanced glycation end prod-
ucts  in progression and complications of diabetes. J Clin Endocrinol Metab
2008;93(4):1143–52, http://dx.doi.org/10.1210/jc.2007-1817.
[78] Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased frac-
ture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab
2009;94(7):2380–6, http://dx.doi.org/10.1210/jc.2008-2498.
[79] Yamamoto M,  Yamaguchi T, Yamauchi M,  Yano S, Sugimoto T. Serum pento-
sidine levels are positively associated with the presence of vertebral fractures
in  postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab
2008;93(3):1013–9, http://dx.doi.org/10.1210/jc.2007-1270.
[80] Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia asso-
ciated with non-insulin-dependent diabetes mellitus: what are the causes?
Diabetes Res Clin Pract 1994;23(1):43–54.
[81] Zhou YJ, Li A, Song YL, Zhou H, Li Y, Tang YS. Role of sclerostin in the bone
loss of postmenopausal chinese women with type 2 diabetes. Chin Med  Sci J
2013;28(3):135–9.
[82] Filippella MG,  Faggiano A, Falchetti A, et al. Risk of fractures and bone abnor-
malities in postmenopausal women with type 2 diabetes mellitus. Clin Cases
Miner Bone Metab 2010;7(2):126–9.
[83] Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K. Anal-
ysis  of an expression profile of genes in the human adipose tissue. Gene
1997;190(2):227–35.
[84] Kanazawa I, Yamaguchi T, Yano S, Yamauchi M,  Yamamoto M, Sugimoto T.
Adiponectin and AMP kinase activator stimulate proliferation, differentiation,
and mineralization of osteoblastic MC3T3-E1 cells. BMC  Cell Biol 2007;8(51.),
http://dx.doi.org/10.1186/1471-2121-8-51.
[85] Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its recep-
tors are expressed in bone-forming cells. Bone 2004;35(4):842–9,
http://dx.doi.org/10.1016/j.bone.2004.06.008.
[86] Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-
specific protein, adiponectin, in obesity. Biochem Biophys Res Commun
1999;257(1):79–83.
[87] Kanazawa I, Yamaguchi T, Yamamoto M,  Yamauchi M,  Yano S, Sug-
imoto T. Relationships between serum adiponectin levels versus
bone mineral density, bone metabolic markers, and vertebral frac-
tures in type 2 diabetes mellitus. Eur J Endocrinol 2009;160(2):265–73,
http://dx.doi.org/10.1530/eje-08-0642.
[88] Patsch JM,  Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2
diabetic postmenopausal women with fragility fractures. J Bone Miner Res
2013;28(2):313–24, http://dx.doi.org/10.1002/jbmr.1763.
[89] Farr JN, Drake MT,  Amin S, Melton 3rd LJ, McCready LK, Khosla S. In vivo
assessment of bone quality in postmenopausal women with type 2 diabetes.
J  Bone Miner Res 2014;29(4):787–95, http://dx.doi.org/10.1002/jbmr.2106.
[90] Garg R, Chen Z, Beck T, et al. Hip geometry in diabetic women:
implications for fracture risk. Metabolism 2012;61(12):1756–62,
http://dx.doi.org/10.1016/j.metabol.2012.05.010.
[91] Beck TJ, Oreskovic TL, Stone KL, et al. Structural adaptation to chang-
ing skeletal load in the progression toward hip fragility: the study
of  osteoporotic fractures. J Bone Miner Res 2001;16(6):1108–19,
http://dx.doi.org/10.1359/jbmr.2001.16.6.1108.
[92] Ishii S, Cauley JA, Greendale GA, et al. Pleiotropic effects of obesity on fracture
risk: the study of women’s health across the nation. J Bone Miner Res 2014,
http://dx.doi.org/10.1002/jbmr.2303.
[93] Moseley KF, Dobrosielski DA, Stewart KJ, Sellmeyer DE, Jan De Beur SM.
Lean  mass predicts hip geometry in men  and women with non-insulin-
requiring type 2 diabetes mellitus. J Clin Densitom 2011;14(3):332–9,
http://dx.doi.org/10.1016/j.jocd.2011.04.007.
[94] Bennett WL,  Maruthur NM,  Singh S, et al. Comparative effectiveness
and safety of medications for type 2 diabetes: an update including new
drugs and 2-drug combinations. Ann Intern Med  2011;154(9):602–13,
http://dx.doi.org/10.7326/0003-4819-154-9-201105030-00336.
[95] Bazelier MT,  Gallagher AM,  van Staa TP, et al. Use of thiazolidinediones and
risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiol Drug Saf
2012;21(5):507–14, http://dx.doi.org/10.1002/pds.3234.
[96] Colhoun HM,  Livingstone SJ, Looker HC, et al. Hospitalised hip frac-
ture risk with rosiglitazone and pioglitazone use compared with
other glucose-lowering drugs. Diabetologia 2012;55(11):2929–37,
http://dx.doi.org/10.1007/s00125-012-2668-0.[97] Bilezikian JP, Josse RG, Eastell R, et al. Rosiglitazone decreases bone min-
eral  density and increases bone turnover in postmenopausal women  with
type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98(4):1519–28,
http://dx.doi.org/10.1210/jc.2012-4018.
2 aturi
http://dx.doi.org/10.1002/jbmr.556.74 E.A.C. de Waard et al. / M
[98] Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone
mineral density in type 2 diabetic men. Diabetes Care 2007;30(6):1574–6,
http://dx.doi.org/10.2337/dc06-2606.
[99] Thrailkill KM,  Lumpkin Jr CK, Bunn RC, Kemp SF, Fowlkes JL. Is
insulin an anabolic agent in bone? Dissecting the diabetic bone
for  clues. Am J Phys Endocrinol Metab 2005;289(5):E735–45,
http://dx.doi.org/10.1152/ajpendo.00159.2005.
[100] Kim JH, Jung MH,  Lee JM,  Son HS, Cha BY, Chang SA. Diabetic periph-
eral neuropathy is highly associated with nontraumatic fractures in Korean
patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2012;77(1):51–5,
http://dx.doi.org/10.1111/j.1365-2265.2011.04222.x.
[101] Cortizo AM,  Sedlinsky C, McCarthy AD, Blanco A, Schurman
L.  Osteogenic actions of the anti-diabetic drug metformin on
osteoblasts in culture. Eur J Pharmacol 2006;536(1–2):38–46,
http://dx.doi.org/10.1016/j.ejphar.2006.02.030.
[102] Jeyabalan J, Viollet B, Smitham P, et al. The anti-diabetic drug metformin
does not affect bone mass in vivo or fracture healing. Osteoporos Int
2013;24(10):2659–70, http://dx.doi.org/10.1007/s00198-013-2371-0.
[103] Monami M,  Cresci B, Colombini A, et al. Bone fractures and hypoglycemic
treatment in type 2 diabetic patients: a case–control study. Diabetes Care
2008;31(2):199–203, http://dx.doi.org/10.2337/dc07-1736.
[104] Puar TH, Khoo JJ, Cho LW,  et al. Association between glycemic
control and hip fracture. J Am Geriatr Soc 2012;60(8):1493–7,
http://dx.doi.org/10.1111/j.1532-5415.2012.04052.x.
[105] Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no
effect on markers of bone formation and resorption or bone min-
eral density in patients with inadequately controlled type 2 dia-
betes mellitus on metformin. Diabetes Obes Metab 2012;14(11):990–9,
http://dx.doi.org/10.1111/j.1463-1326.2012.01630.x.
[106] Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like
peptide-1 receptor agonists and bone fractures: a meta-analysis
of randomized clinical trials. J Diabetes 2013, http://dx.doi.org/
10.1111/1753-0407.12102.[107] Monami M,  Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-
4  inhibitors and bone fractures: a meta-analysis of randomized
clinical trials. Diabetes Care 2011;34(11):2474–6, http://dx.doi.org/
10.2337/dc11-1099.tas 79 (2014) 265–274
[108] Lapane KL, Yang S, Brown MJ,  Jawahar R, Pagliasotti C, Rajpathak S. Sul-
fonylureas and risk of falls and fractures: a systematic review. Drugs Aging
2013;30(7):527–47, http://dx.doi.org/10.1007/s40266-013-0081-0.
[109] Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and
sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 2014,
http://dx.doi.org/10.1007/s00774-014-0581-y.
[110] Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-
1 treatment on bone turnover in normal, type 2 diabetic, and
insulin-resistant states. Calcif Tissue Int 2009;84(6):453–61,
http://dx.doi.org/10.1007/s00223-009-9220-3.
[111] Kanis JA, Melton 3rd LJ, Christiansen C, Johnston CC, Khaltaev N.
The  diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137–41,
http://dx.doi.org/10.1002/jbmr.5650090802.
[112] Yamamoto M,  Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Bone
mineral density is not sensitive enough to assess the risk of vertebral
fractures in type 2 diabetic women. Calcif Tissue Int 2007;80(6):353–8,
http://dx.doi.org/10.1007/s00223-007-9003-7.
[113] Yamaguchi T, Yamamoto M,  Kanazawa I, et al. Quantitative ultrasound and
vertebral fractures in patients with type 2 diabetes. J Bone Miner Metab
2011;29(5):626–32, http://dx.doi.org/10.1007/s00774-011-0265-9.
[114] Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD  and FRAX
score with risk of fracture in older adults with type 2 diabetes. JAMA
2011;305(21):2184–92, http://dx.doi.org/10.1001/jama.2011.715.
[115] WHO  Collaborating Centre for Metabolic Bone Diseases. Available from:
http://www.shef.ac.uk/FRAX/tool.aspx?country=30 [Cited 01.07.14].
[116] Bhattoa HP, Onyeka U, Kalina E, et al. Bone metabolism and the 10-year
probability of hip fracture and a major osteoporotic fracture using the
country-specific FRAX algorithm in men  over 50 years of age with type 2
diabetes mellitus: a case–control study. Clin Rheumatol 2013;32(8):1161–7,
http://dx.doi.org/10.1007/s10067-013-2254-y.
[117] Giangregorio LM,  Leslie WD,  Lix LM,  et al. FRAX underestimates frac-
ture risk in patients with diabetes. J Bone Miner Res 2012;27(2):301–8,[118] Carnevale V, Morano S, Fontana A, et al. Assessment of fracture risk by the
FRAX algorithm in men and women with and without type 2 diabetes mel-
litus: a cross-sectional study. Diabetes Metab Res Rev 2014;30(4):313–22,
http://dx.doi.org/10.1002/dmrr.2497.
